ライフサイエンスコーパス: bimatoprost

1 patients with OHT or OAG received once-daily bimatoprost 0.01 % for 12 weeks.

2 glaucoma (OAG) or ocular hypertension (OHT), bimatoprost 0.01 % improved tolerability while retaining

3 In the Taiwanese clinical setting, bimatoprost 0.01 % provided significant IOP lowering in

4 rrence and severity of hyperemia produced by bimatoprost 0.01 %, and its efficacy, in the Taiwanese c

5 oprost 0.004% (TRAV) and BAK 0.02%-preserved bimatoprost 0.01% (BIM) during late-day time points in p

6 raocular pressure (IOP)-lowering efficacy of bimatoprost 0.03 %.

7 the study eye; the fellow eye began topical bimatoprost 0.03% once daily.

8 % ethanol in DMEM) or the free acid forms of bimatoprost (0.01 or 0.1 microg/mL), latanoprost (0.03 o

9 Holter SBP was significantly higher for bimatoprost (135.1 mmHg vs 128.1 mmHg, p=0.04), while no

10 st to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5

11 They were randomized to LTFC (8 a.m.) or bimatoprost (8 p.m.) and received 24-hour IOP curve at b

12 nist), Butaprost (EP2 receptor agonist), and Bimatoprost (a prostamide) were compared.

13 ether non-eyelash follicles could respond to bimatoprost, a prostamide F(2alpha) analog recently lice

14 nM) > latanoprost acid (EC(50) = 34.7 nM) > bimatoprost acid (EC(50) = 112 nM) > PGF(2alpha) (EC(50)

15 PGF2alphaEA/bimatoprost act via prostaglandin F2alphaFP receptor/FP

16 noprost (isopropyl ester; EC(50) = 778 nM) > bimatoprost (amide; EC(50) = 1410-6940 nM).

17 sent study was to investigate the effects of bimatoprost and a novel prostamide-selective antagonist

18 +/- 0.62 micro M) as well as that induced by bimatoprost and acids of latanoprost and travoprost.

19 The prostamide analog Bimatoprost and an EP2-selective agonist affects only Cy

20 Bimatoprost and latanoprost did not change MMP-2.

21 Bimatoprost and latanoprost increased MMP-9 activity by

22 TIMP-2 was unchanged by bimatoprost and latanoprost, but decreased by unoproston

23 .1+/-10.2 vs 78.2+/-10.1 mmHg (p=0.4) in the bimatoprost and LTFC groups respectively.

24 Bimatoprost and LTFC had similar DBPs and OPPs; SBP was

25 To compare the effect of bimatoprost and the fixed combination latanoprost-timolo

26 ystems were used to test the consequences of bimatoprost and/or AGN 211334 treatment on conventional

27 Therefore, PGF2alpha and Bimatoprost appear to interact with different receptors

28 Bimatoprost, at pharmacologically selective concentratio

29 Bimatoprost (BMP), which is a highly effective ocular hy

30 Bimatoprost did not lead to a significant reduction in I

31 3T3-L1 or human preadipocytes to PGF2alphaEA/bimatoprost during early differentiation inhibits adipog

32 , defined only at the pharmacological level, Bimatoprost effects on Cyr61 and CTGF were studied in th

33 The present study specifically examines bimatoprost effects on the cells that populate human out

34 Bimatoprost effects were insensitive to cholera toxin an

35 OP of -3.2 to -6.4 mmHg was observed for the bimatoprost group compared with -4.2 to -6.4 mmHg for th

36 asurements were also performed after topical bimatoprost in a separate generation of homozygous FP-kn

37 ll dose strengths were comparable to topical bimatoprost in overall IOP reduction through week 16.

38 ptor gene is critical to the IOP response to bimatoprost in the mouse eye.

39 btained in cell culture experiments in which bimatoprost increased hydraulic conductivity of TM cell

40 Bimatoprost increased outflow facility by an average of

41 The topically applied bimatoprost insert may provide an alternative to daily e

42 le patients were randomized 1:1 to receive a bimatoprost insert plus artificial tears twice daily or

43 The findings indicate that bimatoprost interacts with a prostamide receptor in the

44 F2alpha ethanolamide (PGF2alphaEA), of which bimatoprost is a potent synthetic analog.

45 Bimatoprost is a widely used ocular hypotensive agent to

46 ree acids indicate that latanoprost, but not bimatoprost, is hydrolyzed in the mouse eye after topica

47 Tissue and aqueous humor concentrations of bimatoprost, latanoprost, and their C-1 free acids indic

48 aqueous humor and vitreous concentrations of bimatoprost, latanoprost, and their C-1 free acids were

49 Bimatoprost, latanoprost, and travoprost are among the m

50 veness of the prostaglandin analogues (PGAs) bimatoprost, latanoprost, and unoprostone.

51 din F(2 alpha), the ocular hypotensive agent bimatoprost (Lumigan; Allergan, Inc., Irvine, CA) shows

52 n mean IOP was observed over 6 months with a bimatoprost ocular insert and seems to be safe and well

53 A topical bimatoprost ocular insert was compared with twice-daily

54 ollicular signaling system and confirms that bimatoprost offers a novel, low-risk therapeutic approac

55 The effects of bimatoprost on TM and SC cells were inhibited by the pro

56 Adverse events were consistent with bimatoprost or timolol exposure; no unexpected ocular AE

57 The authors observed that bimatoprost produced an immediate and concentration-depe

58 nately, the precise mechanisms that underlie bimatoprost's distinctive impact on aqueous humor dynami

59 bation with AGN 211334 significantly blunted bimatoprost's effects by 95% or 43%, respectively.

60 treatment with AGN 211334 completely blocked bimatoprost's effects, while coincubation decreased its

61 yelash behavior, and scalp follicles contain bimatoprost-sensitive prostamide receptors in vivo.

62 Taken together, results suggest that bimatoprost specifically activates receptors in both cel

63 as more common with topical bimatoprost than Bimatoprost SR (17.3% vs 6.7% of eyes).

64 glaucoma patients (n = 75) were administered Bimatoprost SR (6 mug, 10 mug, 15 mug, or 20 mug) intrac

65 Bimatoprost SR demonstrated favorable efficacy and safet

66 Bimatoprost SR provided rapid, sustained IOP lowering.

67 dable bimatoprost sustained-release implant (Bimatoprost SR).

68 Thus, bimatoprost stimulates human scalp follicles in culture

69 ure (IOP)-lowering effect of a biodegradable bimatoprost sustained-release implant (Bimatoprost SR).

70 ction procedure was more common with topical bimatoprost than Bimatoprost SR (17.3% vs 6.7% of eyes).

71 ug, along with pilocarpine, epinephrine, and bimatoprost that in humans increases the rate of aqueous

72 ficacy and tolerability of fixed-combination bimatoprost/timolol (bim/tim) and dorz/brim/tim in Mexic

73 Bimatoprost, travoprost, latanoprost, unoprostone isopro

74 ificant reduction in IOP was observed in the bimatoprost-treated eye of wild-type mice at 2 hours, wi

75 plant, respectively, vs 8.4 mm Hg in topical bimatoprost-treated pooled fellow eyes (data censored at

76 Both PGF2alpha and Bimatoprost up-regulated Cyr61 mRNA expression in the ca

77 Notably, in TM, SC, and CSM cells, bimatoprost was approximately equipotent to the selectiv

78 se to a single 1.2-microg (4 microL) dose of bimatoprost was measured in the treated and untreated fe